Upload
chad-sila
View
221
Download
0
Embed Size (px)
Citation preview
8/6/2019 Gastric Cancer Presentation
1/27
Gastric Cancer
8/6/2019 Gastric Cancer Presentation
2/27
Presentation 62 year old male who presented with epigastric pain
and weight loss.
EGD: 1.1cm ulcerative lesion in the distal stomach. EUS: Invasion to the muscularis.
Bx: adenocarcinoma.
CT A & P: primary not visualized; no evidence ofmets
8/6/2019 Gastric Cancer Presentation
3/27
Presentation Patient underwent robotic assisted laparascopic distal
gastrectomy with gastrojejunostomy (billroth II) and
D2 lymph node dissection. Path: 0.7 cm focus of invasive adenocarcinoma with
minor component of signet ring extending throughthe muscularis (pT3). 0/19 LN positive (pN0).Margins negative. (gross resection margins 4/2cmproximal and distal respectively).
Final stage: pT3N0M0.
8/6/2019 Gastric Cancer Presentation
4/27
Treatment Recommendations Postoperative chemoradiation
45Gy in 25 fractions to high risk areasgiven concurrently with 5-FU basedchemotherapy.
8/6/2019 Gastric Cancer Presentation
5/27
Treatment Why postoperative chemoradiation?
Intergroup 0116
Randomized phase III trial enrolled patientswith T2+ or N+ disease observation vs.postoperative chemoradiation.
Results: Decreased LRF and increased survival
(MS= 35 vs. 26 months).
8/6/2019 Gastric Cancer Presentation
6/27
Why not Magic Trial?
Technically, patient was eligible.
Favorable risk T2s may be treated with surgeryonly followed by observation (?).
8/6/2019 Gastric Cancer Presentation
7/27
Radiation Technique Targets: gastric bed, anastamoses, residual
stomach, pancreatic head and 1stand 2nd
parts of duodenum. Not covering: lymph nodes.
8/6/2019 Gastric Cancer Presentation
8/27
8/6/2019 Gastric Cancer Presentation
9/27
8/6/2019 Gastric Cancer Presentation
10/27
Background Epidemiology: 22710 new cases and 11780 deaths from gastric
cancer each year in the U.S.
Median age at diagnosis is 65.
Tumor location:
GE junction, cardia, and fundus-35% of cases (incidencerising)
Body-25%
Antrum and distal stomach-40% (incidence falling) Histology: 90% are adenocarcinoma.
Subtypes: Intestinal (older pts, less aggressive) and diffuse(yonger pts, more aggressive)
8/6/2019 Gastric Cancer Presentation
11/27
Workup H&P
EGD with biopsy EUS
CT abdomen and pelvis
CXR (CT chest for GEJ tumor to rule outmediastinal LNs).
PET/CT: Being evaluated, but role stilluncertain.
8/6/2019 Gastric Cancer Presentation
12/27
Staging T stage
T1a: lamina propria or muscularis mucosa
T1b: submucosa T2: muscularis propria T3: subserosa without involving visceral
peritoneum or adjacent structures T4a: Visceral peritoneum
T4b: adjacent structures N stage
N1: 1-2 regional nodes N2: 3-6 N3: 7 or more
8/6/2019 Gastric Cancer Presentation
13/27
Surgery NCCN recommendation for surgery is a
sub-total gastrectomy with D2 lymphnode dissection.
Goals of surgery:
1. >-5 cm proximal/distal margin
2. >=15 LN sampled.
8/6/2019 Gastric Cancer Presentation
14/27
8/6/2019 Gastric Cancer Presentation
15/27
Surgery Why >5cm gross surgical margins?
Annals 1980:
2 cm gross (-) margin30% microscopically
positive margin.
4-6 cm gross (-) margin10% microscopicallypositive margin.
6cm gross (-) margin0% microscopicallypositive
margin.
8/6/2019 Gastric Cancer Presentation
16/27
Surgery Why 15 LN?
5-year Survival as a Function of Stage and #LNs
Examined. (Hundahl et al. Cancer 2000)LNsexam
1A 1B II
1 78% 58% 34%
2-6 75% 48% 26%
7-15 81% 60% 34%
>15 79% 68% 44%
>24 79% 68% 44%
8/6/2019 Gastric Cancer Presentation
17/27
SurgeryD1:
1/2: paracardiac 3/4:
Lesser/Greater Curvature 5/6:
supra/infrapyloric
D2:
7: Left Gastric; 8: Common
Hepatic 9: Celiac 10: Splenic
hilus 11: Splenic
D3: 12: hepatoduodenal
ligament 13: 14: root of
mesentery
8/6/2019 Gastric Cancer Presentation
18/27
Surgery D1 or D2 LND?
Controversial, but D2 dissection standardin Asia and recommended by NCCN.
At least one of the major path studies thatformed the basis for radiotherapy guidelineswas based on patterns of failure in patients
who had undergone D2 dissections.
8/6/2019 Gastric Cancer Presentation
19/27
Radiation-Why? Intergroup 0116 demonstrated a survival benefit to
postoperative chemo-RT. Impetus for this trial were retrospective studies which
demonstrated a significant locoregional component to failure after
surgery.
Of note, approximately 20% of recurrences occurred inthe local regional area as the only site of initial failure.
8/6/2019 Gastric Cancer Presentation
20/27
8/6/2019 Gastric Cancer Presentation
21/27
Risk of Local vs. Regional Failure as a function ofT and N stage. (Landry et al. 1990).
Increased risk of local failure with disease extendingbeyond the mucosa--20% overall (T3 and T4 disease>35%)
Increased risk of regional failure with nodal positivity.
Low rate of regional failure in node-negative patients evenwith advanced T-stage. ( 2/37 patients in Mass General
Series with T3 or T4 disease)
8/6/2019 Gastric Cancer Presentation
22/27
Which Lymph Nodes?
8/6/2019 Gastric Cancer Presentation
23/27
Putting it all together Classic guidelines consider 3 areas:
gastric bed, residual stomach, andlymph nodes.
For present case, plan was to treat gastricbed (including pancreatic head and 1stand
2nd
portion of duodenum) and residualstomach, but not the lymph nodes.
8/6/2019 Gastric Cancer Presentation
24/27
Gastric Bed Why Gastric Bed?
Significant increase in local failure (>20%)
when disease has extended beyond themucosal layers.
8/6/2019 Gastric Cancer Presentation
25/27
Gastric Bed Gastric bed usually refers to preop location of stomach + any
anastamoses. Guidelines will additionally specify a portion ofpancreas and/or duodenum to include in the gastric bed
based on location of primary.
Prox 1/3: tail of pancreas
Middle 1/3: body of pancreas
Distal 1/3: head of pancreas
and 1st and 2nd portion of
duodenum.
8/6/2019 Gastric Cancer Presentation
26/27
Residual Stomach Included in present case. Why?
Surgical Margins
8/6/2019 Gastric Cancer Presentation
27/27
Lymph Nodes Not covered. Why?
>15 LN sampled. All negative.
Operative series demonstrated low risk ofregional failure in node-negative patients whounderwent D2 dissection even with advancedT-stage disease.